MyoKardia (MYOK) Names New Chief Medical Officer
- Wall Street falls with financials, other post-election gainers
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
- After-Hours Stock Movers 01/17: (SHLO) Higher; (GIMO) (AFAM) (CSX) Lower (more...)
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
MyoKardia, Inc. (Nasdaq: MYOK) announced that Marc Semigran, M.D., has joined the Company as chief medical officer. In his new position, Dr. Semigran will oversee clinical development and lead MyoKardia’s clinical trial strategy.
“We are excited to welcome Marc to MyoKardia as chief medical officer,” said Tassos Gianakakos, chief executive officer. “His extraordinary medical and scientific expertise and strong relationships in the cardiovascular and clinical communities will be invaluable as MyoKardia pursues its mission to change the world for patients with serious cardiovascular disease through bold and innovative science.”
“Dr. Semigran shares MyoKardia’s values, particularly with respect to Patients First and Passion for Science, and I am confident his leadership will enable MyoKardia to deliver first-ever, potentially transformative therapies for patients with heritable cardiomyopathies,” said Mr. Gianakakos.
Most recently, Dr. Semigran led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran has been a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School.
“MyoKardia is a great innovator in cardiovascular therapy, and the Company is emblematic of the science-driven, precision medicine approach that will bring about much-needed therapies for patients,” said Dr. Semigran. “I am delighted to have the opportunity to lead MyoKardia’s clinical programs at such a pivotal time for the Company.”
Dr. Semigran has published more than 140 peer-reviewed papers in cardiomyopathy, heart failure and cardiac transplantation, and served as editor for a leading textbook on heart failure. He is a recipient of numerous National Institutes of Health and industry research awards, and has served as principal or co-investigator in several major clinical trials across various therapeutic areas. In addition, he has served in scientific and medical advisory capacities to such companies as GSK, Medtronic plc and Bayer.
Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roka Bioscience (ROKA) Names Mary Duseau as CEO; Paul Thomas to Assume Role as Chairman
- Materion Corp. (MTRN) Announces Two Patents for Fabrication Process of BrushForm 158
- JCPenney (JCP) Launches Nike (NKE) Shops
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!